IP Library › Granted Patent US 7,141,552
Granted Patent B2
US 7,141,552 · App. 10/790,182 · Granted Nov 28, 2006

Use of lipid conjugates in the treatment of diseases

Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,141,552
App. No.
10/790,182
Granted
Nov 28, 2006
Kind
B2
Abstract

The invention provides a method for treating a subject suffering from an intestinal disease, including, inter alia, Crohn's disease, ulcerative colitis, immuno-inflammatory intestinal injury, drug-induced enteropathy and ischemia-induced intestinal injury. This invention further provides a pharmaceutical composition for treating a subject suffering from an intestinal disease, including, inter alia, a lipid or phospholipid moiety bonded to a physiologically acceptable monomer, dimer, oligomer, or polymer, and a pharmaceutically acceptable carrier or excipient.

Claims (13)

1. A method of treating a subject suffering from an intestinal disease, comprising the step of administering to said subject an effective amount of a lipid or phospholipid moiety bonded via an amide or ester linkage to a glycosaminoglycan, thereby treating said subject suffering from said intestinal disease.

2. The method of claim 1 , wherein said intestinal disease is Crohn's disease, ulcerative colitis, immuno-inflammatory intestinal injury, drug-induced enteropathy, ischemia-induced intestinal injury or any combination thereof.

3. The method of claim 1 , wherein said phospholipid moiety is phosphatidylethanolamine.

4. The method of claim 1 , wherein said lipid or phospholipid moiety bonded to a glycoaminoglycan is administered as part of a pharmaceutical composition.

5. The method of claim 1 , wherein said glycosaminoglycan is hyaluronic acid.

6. The method of claim 1 , wherein said glycosaminoglycan is heparin.

7. The method of claim 1 , wherein said glycosaminoglycan is chondroitin sulfate.

8. The method of claim 7 , wherein said chondroitin sulfate is chondrotin-6-sulfate, chondroitin-4-sulfate, or a derivative thereof.

9. The method of claim 3 , wherein said phosphatidylethanolamine is dimyristoyl phosphatidylethanolamine.

10. The method of claim 3 , wherein said phosphatidylethanolamine is dipalmitoyl phosphatidylethanolamine.

11. The method of claim 1 , wherein said intestinal disease is immuno-inflammatory intestinal injury.

12. The method of claim 1 , wherein said intestinal disease is Crohn's disease.

13. The method of claim 1 , wherein said intestinal disease is ulcerative colitis.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2018
From: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD
To: YEDGAR, SAUL
Reel/Frame 046006/0942 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2004
From: YEDGAR, SAUL; LIGUMSKI, MOSHE; KRIMSKY, MIRON
To: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
Reel/Frame 015047/0937 →
Continuity (3)
Continuation In Part 0975676500 · Jan 10, 2001
Provisional Application 6017490700 · Jan 10, 2000
Related Publication 20040229842A1 · Nov 18, 2004